Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Evaluating the Effectiveness and Safety of Vedolizumab in Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials2025
2. 2Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies2024 · 3 citations
3. 3Association of tissue lymphocyte immunophenotype and clinical outcomes: A prospective study in patients with ulcerative colitis treated with vedolizumabCohort Study · 2026
4. 4Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor AntagonistsLate-Phase Clinical Trial · 2016 · 228 citations
5. 5Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.2024 · 3 citations